104 related articles for article (PubMed ID: 26637407)
1. Abiraterone-induced rhabdomyolysis: A case report.
Moore DC; Moore A
J Oncol Pharm Pract; 2017 Mar; 23(2):148-151. PubMed ID: 26637407
[TBL] [Abstract][Full Text] [Related]
2. Abiraterone-induced rhabdomyolysis resulting in acute kidney injury: A case report and review of the literature.
Dineen M; Hansen E; Guancial E; Sievert L; Sahasrabudhe D
J Oncol Pharm Pract; 2018 Jun; 24(4):314-318. PubMed ID: 28355968
[TBL] [Abstract][Full Text] [Related]
3. Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report.
Neyra JA; Rocha NA; Bhargava R; Vaidya OU; Hendricks AR; Rodan AR
BMC Nephrol; 2015 Jul; 16():118. PubMed ID: 26220655
[TBL] [Abstract][Full Text] [Related]
4. Study of cases of abiraterone discontinuation due to toxicity in pre-chemotherapy after 1 year's experience.
Ramudo-Cela L; Balea-Filgueiras J; Vizoso-Hermida JR; Martín-Herranz I
J Oncol Pharm Pract; 2017 Dec; 23(8):615-619. PubMed ID: 27753628
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone experience in a patient with metastatic castration-resistant prostate cancer on hemodialysis.
Karakurt Eryılmaz M; Karaağaç M
J Oncol Pharm Pract; 2019 Dec; 25(8):2031-2034. PubMed ID: 31694496
[TBL] [Abstract][Full Text] [Related]
6. [Abiraterone in castration resistant prostate cancer.].
Juárez Soto A; Caballero Cobos R; Campanario Pérez R; Saiz Marenco R; Herrera Torres M; Gamaza Martínez R; Amores Bermúdez J
Arch Esp Urol; 2018 Sep; 71(8):651-663. PubMed ID: 30319125
[TBL] [Abstract][Full Text] [Related]
7. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
9. Is dexamethasone a better partner for abiraterone than prednisolone?
Dizdar O
Oncologist; 2015 May; 20(5):e13. PubMed ID: 25888271
[TBL] [Abstract][Full Text] [Related]
10. Statin-Induced Rhabdomyolysis Due to Pharmacokinetic Changes From Biliary Obstruction in a Patient With Metastatic Prostate Cancer.
Desikan SP; Sobash P; Fisher A; Desikan R
J Investig Med High Impact Case Rep; 2020; 8():2324709620947275. PubMed ID: 32755252
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.
Kwak C; Wu TT; Lee HM; Wu HC; Hong SJ; Ou YC; Byun SS; Rhim HY; Kheoh T; Wan Y; Yeh H; Yu MK; Kim CS
Int J Urol; 2014 Dec; 21(12):1239-44. PubMed ID: 25099185
[TBL] [Abstract][Full Text] [Related]
12. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
Maughan BL; Xhou XC; Suzman DL; Nadal R; Bassi S; Schweizer MT; Antonarakis ES
Prostate; 2015 Nov; 75(15):1814-20. PubMed ID: 26306637
[TBL] [Abstract][Full Text] [Related]
13. Management of anticoagulation in patients with metastatic castration-resistant prostate cancer receiving abiraterone + prednisone.
Dubinsky S; Thawer A; McLeod AG; McFarlane TRJ; Emmenegger U
Support Care Cancer; 2019 Sep; 27(9):3209-3217. PubMed ID: 31073853
[TBL] [Abstract][Full Text] [Related]
14. Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice.
Woo HH; Begbie S; Gogna K; Mainwaring PN; Murphy DG; Parnis F; Steer C; Davis ID
Asia Pac J Clin Oncol; 2014 Sep; 10(3):228-36. PubMed ID: 25132163
[TBL] [Abstract][Full Text] [Related]
15. Cancer therapeutics-related cardiac dysfunction in a patient treated with abiraterone for castration-resistant prostate cancer.
Tsugu T; Nagatomo Y; Nakajima Y; Kageyama T; Akise Y; Endo J; Itabashi Y; Murata M; Mitamura H
J Med Ultrason (2001); 2019 Apr; 46(2):239-243. PubMed ID: 30151629
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer.
Leibowitz-Amit R; Templeton AJ; Alibhai SM; Knox JJ; Sridhar SS; Tannock IF; Joshua AM
J Geriatr Oncol; 2015 Jan; 6(1):23-8. PubMed ID: 25301537
[TBL] [Abstract][Full Text] [Related]
17. [Abiraterone: Overall survival benefit and subsidiary issues].
Vignot S
Bull Cancer; 2015 Jun; 102(6):487-8. PubMed ID: 25976372
[No Abstract] [Full Text] [Related]
18. Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
Francini E; Fiaschi AI; Petrioli R; Bianco V; Laera L; Francini F; Roviello G
Anticancer Drugs; 2015 Sep; 26(8):910-1. PubMed ID: 26207428
[No Abstract] [Full Text] [Related]
19. Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: A case report and review of the literature.
Ould-Nana I; Cillis M; Gizzi M; Gillion V; Hantson P; Gérard L
J Oncol Pharm Pract; 2021 Jan; 27(1):216-219. PubMed ID: 32397905
[TBL] [Abstract][Full Text] [Related]
20. Urological cancer: abiraterone treatment improves overall survival in patients with mCRPC.
Sidaway P
Nat Rev Clin Oncol; 2015 Mar; 12(3):128. PubMed ID: 25645601
[No Abstract] [Full Text] [Related]
[Next] [New Search]
